Detalhe da pesquisa
1.
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.
J Antimicrob Chemother
; 79(5): 1133-1141, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546974
2.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Clin Infect Dis
; 76(5): 861-870, 2023 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36259527
3.
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Clin Infect Dis
; 77(7): 991-1009, 2023 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207617
4.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
J Antimicrob Chemother
; 78(9): 2361-2365, 2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37539492
5.
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
J Antimicrob Chemother
; 77(7): 1980-1988, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411401
6.
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
J Antimicrob Chemother
; 76(9): 2380-2393, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34120186
7.
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.
J Antimicrob Chemother
; 75(11): 3334-3343, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32737482
8.
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Clin Infect Dis
; 68(4): 597-606, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29912307
9.
Cholesterol efflux responds to viral load and CD4 counts in HIV+ patients and is dampened in HIV exposed.
J Lipid Res
; 59(11): 2108-2115, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30213800
10.
Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
J Antimicrob Chemother
; 73(7): 1965-1971, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29608685
11.
Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses.
Nanomedicine
; 14(2): 339-351, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29157976
12.
The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity.
Retrovirology
; 14(1): 50, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29121950
13.
Tolerability of integrase inhibitors in a real-life setting.
J Antimicrob Chemother
; 72(6): 1752-1759, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28333231
14.
Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial.
J Antimicrob Chemother
; 72(3): 829-836, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27999018
15.
Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity.
Nanomedicine
; 13(2): 601-609, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27565689
16.
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Clin Infect Dis
; 63(1): 122-32, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27048747
17.
Increased expression with differential subcellular location of cytidine deaminase APOBEC3G in human CD4(+) T-cell activation and dendritic cell maturation.
Immunol Cell Biol
; 94(7): 689-700, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26987686
18.
Beyond viral suppression of HIV - the new quality of life frontier.
BMC Med
; 14(1): 94, 2016 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27334606
19.
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.
J Antimicrob Chemother
; 71(7): 1975-81, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27021341
20.
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.
Clin Infect Dis
; 60(5): 811-20, 2015 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25389256